Interaction Checker

Irinotecan interactions

Irinotecan (Camptosar, Onivyde) has 137 documented interactions across the FDA labels and fact sheets we index: 113 major, 21 moderate, 2 minor, and 1 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (113)

  • Acetazolamidecarbonic anhydrase inhibitorMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Amiloridepotassium-sparing diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • AmiodaroneantiarrhythmicMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • AtazanavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Atenolol and chlorthalidonebeta blockerMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • AtropineanticholinergicMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Atropine and pralidoximeanticholinergicMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Benazepril and hydrochlorothiazideACE inhibitorMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Bethanecholcholinergic agonistMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • BisacodyllaxativeMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Bisoprolol and hydrochlorothiazidebeta blockerMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • BosentanCYP3A4 inducerMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Bumetanideloop diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Candesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • CarbamazepineanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • CenobamateanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Cevimelinecholinergic agonistMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Chlorothiazidethiazide diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Chlorthalidonethiazide diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • CimetidineH2 blockerMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • ClobazambenzodiazepineMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • CyclosporineimmunosuppressantMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • DarunavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Darunavir and cobicistatantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Deferasiroxiron supplementMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Difenoxin and atropineMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Diltiazemcalcium channel blockerMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Diphenoxylate and atropineMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • DocusatelaxativeMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • DronedaroneantiarrhythmicMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • EfavirenzantiretroviralMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Enalapril and hydrochlorothiazideACE inhibitorMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Eplerenonealdosterone antagonistMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Erythromycinmacrolide antibioticMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Ethacrynic acidloop diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • EtravirineantiretroviralMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • EverolimusimmunosuppressantMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • FosamprenavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Fosinopril and hydrochlorothiazideACE inhibitorMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • FosphenytoinanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Furosemideloop diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • GriseofulvinantifungalMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Hydrochlorothiazidethiazide diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • ImatinibCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Indapamidethiazide diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Irbesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • IsoniazidantibioticMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Itraconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • LactuloselaxativeMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • LenacapavirantiretroviralMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Lisinopril and hydrochlorothiazideACE inhibitorMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • LoperamideQT-prolonging drugMajor

    Late diarrhea can be life threatening and should be treated promptly with loperamide. (Irinotecan label, Boxed warning)

  • Lopinavir and ritonavirantiretroviralMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • LorlatinibCYP3A4 inducerMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Losartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Metolazonethiazide diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Metoprolol and hydrochlorothiazidebeta blockerMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • MifepristoneCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Mirabegronbeta-adrenergic agonistMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • MitapivatCYP3A4 inducerMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • MitotaneCYP3A4 inducerMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • ModafinilCNS stimulantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Nafcillinpenicillin antibioticMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • NefazodoneantidepressantMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • NevirapineantiretroviralMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Olmesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • OxcarbazepineanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • PerampanelanticonvulsantMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Phenobarbital, hyoscyamine, atropine, and scopolaminebarbiturateMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Phentermine and topiramateCNS stimulantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Pilocarpinecholinergic agonistMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Polyethylene glycol 3350laxativeMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Posaconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • PrimidoneanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Pyridostigminecholinesterase inhibitorMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Quinapril and hydrochlorothiazideACE inhibitorMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • RanolazineQT-prolonging drugMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • RifabutinantibioticMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • RifampinantibioticMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • RifapentineantibioticMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • RitonavirantiretroviralMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • ScopolamineanticholinergicMajor

    Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (Irinotecan label, Boxed warning)

  • Senna (sennosides)laxativeMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Sofosbuvir and velpatasvirantiviralMajor

    Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (Sofosbuvir and velpatasvir label, Drug interactions)

  • Spironolactonealdosterone antagonistMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Spironolactone and hydrochlorothiazidealdosterone antagonistMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Suvorexantsedative-hypnoticMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • SuzetrigineCYP3A4 inducerMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Telmisartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Ticagrelorantiplatelet agentMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • TopiramateanticonvulsantMajor

    • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Torsemideloop diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Triamterenepotassium-sparing diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Triamterene and hydrochlorothiazidepotassium-sparing diureticMajor

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Valsartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    Avoid diuretics or laxatives in patients with diarrhea. (Irinotecan label, Warnings and precautions)

  • Verapamilcalcium channel blockerMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (Irinotecan label, Drug interactions)

Moderate interactions (21)

  • BrivaracetamanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • Cannabidiol (prescription)anticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • CapecitabineantimetaboliteModerate

    Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (Capecitabine label, Drug interactions)

  • ClonazepambenzodiazepineModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • Divalproex (valproate)anticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • EltrombopagOATP1B1 inhibitorModerate

    …(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (Eltrombopag label, Drug interactions)

  • EthosuximideanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • FelbamateanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • GabapentinanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • GemfibrozilfibrateModerate

    Coadministration of CAMPTOSAR with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irinotecan or SN-38. (Irinotecan label, Drug interactions)

  • LacosamideanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • LamotrigineanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • LevetiracetamanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • MethsuximideanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • PregabalinanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • RolapitantCYP2D6 inhibitorModerate

    BCRP Substrates with a Narrow Therapeutic Index (e.g., methotrexate, topotecan, or irinotecan) Clinical Impact: Increased plasma concentrations of BCRP substrates (e.g., methotrexate, topotecan, or irinotecan) may result in potential adverse reactions [see Clinical Pharmacology (12.3) ]. (Rolapitant label, Drug interactions)

  • RufinamideanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • TiagabineanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • Valproic acidanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • VigabatrinanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

  • ZonisamideanticonvulsantModerate

    Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. (Irinotecan label, Drug interactions)

Minor mentions (2)

  • FluorouracilantimetaboliteMinor

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (Irinotecan label, Drug interactions)

  • LeucovorinMinor

    5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. (Irinotecan label, Drug interactions)

No significant interaction reported (1)

  • BevacizumabNo interaction

    Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (Bevacizumab label, Drug interactions)

Check Irinotecan against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.